NCT00271765 - A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

June 30, 2006

Conditions

Acute Myocardial Infarction

Interventions

DRUG

INO-1001

Trial Locations (16)

West Virginia University, Morgantown

Rambam Medical Center, Haifa

Holy Cross Hospital, Fort Lauderdale

Toledo Hospital, Toledo

Porter Hospital, Valparaiso

Hasharon Medical Center, Petah Tikva

Rabin Medical Center, Petah Tikva

St. Paul Heart Clinic, Saint Paul

Black Hills Cardiovascular Research, Rapid City

Meir Medical Center, Kfar Saba

Newark

Hospital of the University of Pennsylvania, Philadelphia

Burlington

Sentara Norfolk General Hospital, Norfolk

Rehovot

Assaf Harofe Medical Centre, Ẕerifin